Visiongain Publishes Diabetic Foot Ulcer (DFU) Treatment Market Report 2020-2030

03 August 2020
Pharma

Visiongain has launched a new pharma report Diabetic Foot Ulcer (DFU) Treatment Market Report 2020-2030: Prospects by Product Type (Advance Wound Dressings, Skin Substitutes, Growth Factors, Negative Pressure Wound Therapy Devices), Ulcer Type (Neuropathic Ulcers, Ischemic Ulcers, Neuro-Ischemic Ulcers), End User (Hospitals, Specialty Clinics, Long Term Care Centers, Ambulatory Surgical Center), and Geography.

The global diabetic foot ulcer (DFU) treatment market is projected to grow at a lucrative CAGR of ~xx% and anticipated to surpass USD xx billion by 2030.

Diabetic Foot Ulcer (DFU) is mainly caused by disorders of the vascular system & neuropathy. The neuropathic problems lead to loss of sensation in legs & foot, thus leading to a disorder known as diabetic neuropathy. Improper circulation of the blood contributes to ulceration. Diabetic foot ulcers are difficult to cure because the wound does not get enough nutrients/oxygen from the blood, thus resulting in the risk of lower limb amputation & therefore needs to be treated to avoid foot amputation along with stopping the growth and spreading ulcers to other parts of the body. The most common cause of diabetic foot ulcers wounded feet, poor circulation nerve damage, & hyperglycemia. The initial symptoms comprise unusual swelling, redness, irritation, & stenches.

The global diabetic foot ulcer market is growing on account of growing diabetes and rapidly growing geriatric population worldwide. Nevertheless, high cost related to disease management is anticipated to impede market growth over the forecast period. There is a lack of healthcare facilities in most emerging and underdeveloped economies which is restraining the market growth. However, the adoption of novel therapeutics improved biologics, technological advancements & continued prioritization to avoid surgeries & amputations are anticipated to offset limitations affecting the global market growth.

Major companies operating in the diabetic foot ulcer treatment industry are launching advanced products to maintain their share in the global market. Over the past few decades, a growing number of manufacturers have focused on developing innovative wound dressings for the treatment of diabetic foot ulcers. It includes new dressings with the potential to impart moisture balance with prolonged action time, extended oxygen permeability, antimicrobial activity, stimulation of growth factor, and the ability to promote autolytic debridement, thereby promoting the cycle of epithelialization process.

North America holds the majority of market share owing to the increasing number of diabetic patients, advance healthcare facilities, the presence of major manufacturers in the region, and growing awareness among people are key factors responsible for regional market growth. Furthermore, increasing usage of novel biologics & wound care tools for treating such ulcers, are leading to North America's regional market dominance.

However, Asia Pacific diabetic foot ulcer treatment market is anticipated to grow with the highest CAGR over the forecast period owing to growing patient pool in emerging economies of China & India, coupled with rising prevalence of diabetes, growing healthcare expenditure, rising disposable income, growing health awareness, and penetration of major global players in the region.

Some of the major players operating in this industry are 3M Healthcare, Acelity L.P. Inc., B. Braun Melsungen AG, Coloplast A/S, ConvaTec, Inc., Medline Industries, Inc., Medtronic Plc., Molnlycke Health Care AB, Organogenesis, Inc., Smith & Nephew Plc, Derma Sciences Inc., Sigvaris Inc., Innocoll Holdings plc., Osiris, BSN Medical GMBH, Thermo fisher, Integra LifeSciences among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever